vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Clear Channel Outdoor Holdings, Inc. (CCO). Click either name above to swap in a different company.
Clear Channel Outdoor Holdings, Inc. is the larger business by last-quarter revenue ($461.5M vs $284.0M, roughly 1.6× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 1.7%, a 94.6% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs 8.2%). Over the past eight quarters, Clear Channel Outdoor Holdings, Inc.'s revenue compounded faster (18.8% CAGR vs 17.5%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Clear Channel Outdoor Holdings, Inc. is a multinational corporation focused on outdoor advertising. The company is based in San Antonio, Texas.
ACAD vs CCO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $461.5M |
| Net Profit | $273.6M | $8.0M |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | 23.3% |
| Net Margin | 96.3% | 1.7% |
| Revenue YoY | 9.4% | 8.2% |
| Net Profit YoY | 90.3% | 144.8% |
| EPS (diluted) | $1.61 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $461.5M | ||
| Q3 25 | $278.6M | $405.6M | ||
| Q2 25 | $264.6M | $402.8M | ||
| Q1 25 | $244.3M | $334.2M | ||
| Q4 24 | $259.6M | $426.7M | ||
| Q3 24 | $250.4M | $375.2M | ||
| Q2 24 | $242.0M | $376.5M | ||
| Q1 24 | $205.8M | $326.8M |
| Q4 25 | $273.6M | $8.0M | ||
| Q3 25 | $71.8M | $-60.1M | ||
| Q2 25 | $26.7M | $9.5M | ||
| Q1 25 | $19.0M | $62.5M | ||
| Q4 24 | $143.7M | $-17.9M | ||
| Q3 24 | $32.8M | $-32.5M | ||
| Q2 24 | $33.4M | $-39.2M | ||
| Q1 24 | $16.6M | $-89.7M |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — | ||
| Q1 24 | 88.8% | — |
| Q4 25 | 6.1% | 23.3% | ||
| Q3 25 | 12.8% | 19.9% | ||
| Q2 25 | 12.2% | 19.2% | ||
| Q1 25 | 7.9% | 13.5% | ||
| Q4 24 | 59.1% | 23.5% | ||
| Q3 24 | 12.6% | 17.8% | ||
| Q2 24 | 12.6% | 18.2% | ||
| Q1 24 | 7.4% | 13.4% |
| Q4 25 | 96.3% | 1.7% | ||
| Q3 25 | 25.8% | -14.8% | ||
| Q2 25 | 10.1% | 2.4% | ||
| Q1 25 | 7.8% | 18.7% | ||
| Q4 24 | 55.4% | -4.2% | ||
| Q3 24 | 13.1% | -8.7% | ||
| Q2 24 | 13.8% | -10.4% | ||
| Q1 24 | 8.0% | -27.4% |
| Q4 25 | $1.61 | $0.01 | ||
| Q3 25 | $0.42 | $-0.12 | ||
| Q2 25 | $0.16 | $0.02 | ||
| Q1 25 | $0.11 | $0.13 | ||
| Q4 24 | $0.86 | $-0.03 | ||
| Q3 24 | $0.20 | $-0.07 | ||
| Q2 24 | $0.20 | $-0.08 | ||
| Q1 24 | $0.10 | $-0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $190.0M |
| Total DebtLower is stronger | — | $5.1B |
| Stockholders' EquityBook value | $1.2B | $-3.4B |
| Total Assets | $1.6B | $3.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $190.0M | ||
| Q3 25 | $258.0M | $155.0M | ||
| Q2 25 | $253.6M | $138.6M | ||
| Q1 25 | $217.7M | $395.8M | ||
| Q4 24 | $319.6M | $109.7M | ||
| Q3 24 | $155.1M | $201.1M | ||
| Q2 24 | $177.1M | $189.3M | ||
| Q1 24 | $204.7M | $193.2M |
| Q4 25 | — | $5.1B | ||
| Q3 25 | — | $5.1B | ||
| Q2 25 | — | $5.1B | ||
| Q1 25 | — | $5.3B | ||
| Q4 24 | — | $5.7B | ||
| Q3 24 | — | $5.7B | ||
| Q2 24 | — | $5.7B | ||
| Q1 24 | — | $5.7B |
| Q4 25 | $1.2B | $-3.4B | ||
| Q3 25 | $917.3M | $-3.5B | ||
| Q2 25 | $822.4M | $-3.4B | ||
| Q1 25 | $765.2M | $-3.4B | ||
| Q4 24 | $732.8M | $-3.6B | ||
| Q3 24 | $577.2M | $-3.6B | ||
| Q2 24 | $516.7M | $-3.6B | ||
| Q1 24 | $464.0M | $-3.5B |
| Q4 25 | $1.6B | $3.8B | ||
| Q3 25 | $1.3B | $3.8B | ||
| Q2 25 | $1.2B | $3.8B | ||
| Q1 25 | $1.1B | $4.0B | ||
| Q4 24 | $1.2B | $4.8B | ||
| Q3 24 | $976.9M | $4.6B | ||
| Q2 24 | $914.1M | $4.5B | ||
| Q1 24 | $855.1M | $4.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $56.3M |
| Free Cash FlowOCF − Capex | — | $30.3M |
| FCF MarginFCF / Revenue | — | 6.6% |
| Capex IntensityCapex / Revenue | — | 5.6% |
| Cash ConversionOCF / Net Profit | -0.18× | 7.04× |
| TTM Free Cash FlowTrailing 4 quarters | — | $32.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $56.3M | ||
| Q3 25 | $74.3M | $56.2M | ||
| Q2 25 | $64.0M | $-12.6M | ||
| Q1 25 | $20.3M | $14.9M | ||
| Q4 24 | $40.4M | $29.3M | ||
| Q3 24 | $63.2M | $54.5M | ||
| Q2 24 | $25.0M | $30.8M | ||
| Q1 24 | $29.1M | $-34.8M |
| Q4 25 | — | $30.3M | ||
| Q3 25 | $73.9M | $41.4M | ||
| Q2 25 | — | $-29.2M | ||
| Q1 25 | — | $-10.6M | ||
| Q4 24 | — | $-27.8M | ||
| Q3 24 | $63.2M | $21.0M | ||
| Q2 24 | — | $5.2M | ||
| Q1 24 | — | $-61.0M |
| Q4 25 | — | 6.6% | ||
| Q3 25 | 26.5% | 10.2% | ||
| Q2 25 | — | -7.2% | ||
| Q1 25 | — | -3.2% | ||
| Q4 24 | — | -6.5% | ||
| Q3 24 | 25.2% | 5.6% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | -18.7% |
| Q4 25 | — | 5.6% | ||
| Q3 25 | 0.1% | 3.7% | ||
| Q2 25 | — | 4.1% | ||
| Q1 25 | — | 7.6% | ||
| Q4 24 | — | 13.4% | ||
| Q3 24 | 0.0% | 8.9% | ||
| Q2 24 | — | 6.8% | ||
| Q1 24 | — | 8.0% |
| Q4 25 | -0.18× | 7.04× | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 2.40× | -1.32× | ||
| Q1 25 | 1.07× | 0.24× | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | — | ||
| Q2 24 | 0.75× | — | ||
| Q1 24 | 1.76× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
CCO
Segment breakdown not available.
